EUVIMEDEUVIMED entdecken
Crossref

Clinical and pathophysiological rationale for topical therapy in rosacea

Оlga I. Letiaeva, Tatyana V. Trapeznikova, Anastasia N. Shafigullina

Russian Journal of Skin and Venereal Diseases · 18.08.2026 · 29 (5) · 566-579

DOI: 10.17816/dv716603 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Russian Journal of Skin and Venereal Diseases, online erschienen am 18.08.2026. Verfasst von Оlga I. Letiaeva und 2 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rosacea is one of the most common dermatoses and more often manifests during the fifth or sixth decade of life; however, over the past decade, a consistent tendency toward onset at age under 30 has been observed. The pathological process is chronic and prone to relapses, which inevitably leads to social maladjustment, anxiety disorders, and depression. Significant progress has been made in the study of the pathogenesis of rosacea over the past decade, and two leading mechanisms have been identified—imbalance of innate immunity factors and neurovascular disorders. Current clinical recommendations of the Russian Society of Dermatovenereologists and Cosmetologists and foreign guidelines for the management of patients with rosacea prescribe that all patients use dermocosmetic products for cleansing and moisturizing sensitive skin, as well as photoprotective agents at any time of the year with a sun protection factor of at least 30. In the erythematotelangiectatic subtype of rosacea, 0.5% brimonidine tartrate gel is the drug of choice. Ivermectin 1% is a first-line topical therapy for the papulopustular subtype of rosacea, and at all severity levels, starting from mild. Our work demonstrates the management tactics for patients with various rosacea subtypes using topical therapy. A series of clinical cases and photographic materials demonstrating the results of the treatment are presented. Depending on the clinical situation, either 0.5% brimonidine tartrate gel or ivermectin 1% cream was used as the therapeutic agent. The observations demonstrated clinical efficacy and a favorable safety profile of the medicinal products used both during the treatment phase and as maintenance therapy.

Zitieren

APA

Letiaeva, О. I., Trapeznikova, T. V., & Shafigullina, A. N. (2026). Clinical and pathophysiological rationale for topical therapy in rosacea. Russian Journal of Skin and Venereal Diseases, 29(5), 566-579. https://doi.org/10.17816/dv716603

Vancouver

Letiaeva ОI, Trapeznikova TV, Shafigullina AN. Clinical and pathophysiological rationale for topical therapy in rosacea. Russian Journal of Skin and Venereal Diseases. 2026;29(5):566-579. doi:10.17816/dv716603

BibTeX
@article{Letiaeva2026,
  author = {Letiaeva, Оlga I. and Trapeznikova, Tatyana V. and Shafigullina, Anastasia N.},
  title = {Clinical and pathophysiological rationale for topical therapy in rosacea},
  journal = {Russian Journal of Skin and Venereal Diseases},
  year = {2026},
  volume = {29},
  number = {5},
  pages = {566--579},
  doi = {10.17816/dv716603}
}
Kostenlos starten →